834 related articles for article (PubMed ID: 7530168)
21. Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens.
Grogan L; Corbally N; Dervan PA; Byrne A; Carney DN
Ann Oncol; 1994; 5 Suppl 2():47-51. PubMed ID: 7515647
[TBL] [Abstract][Full Text] [Related]
22. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas.
Guglielmi C; Gherlinzoni F; Amadori S; Mazza P; Mantovani L; Lauria F; Martelli M; Zinzani PL; Greco V; Poletti G
Haematologica; 1989; 74(6):563-9. PubMed ID: 2483401
[TBL] [Abstract][Full Text] [Related]
23. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
[TBL] [Abstract][Full Text] [Related]
24. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
[TBL] [Abstract][Full Text] [Related]
25. Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients.
Todeschini G; Ambrosetti A; Meneghini V; Pizzolo G; Menestrina F; Chilosi M; Benedetti F; Veneri D; Cetto GL; Perona G
J Clin Oncol; 1990 May; 8(5):804-8. PubMed ID: 1692089
[TBL] [Abstract][Full Text] [Related]
26. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B
J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302
[TBL] [Abstract][Full Text] [Related]
27. Treatment of aggressive non-Hodgkin' lymphomas. Lessons from the past 10 years.
Fisher RI
Cancer; 1994 Nov; 74(9 Suppl):2657-61. PubMed ID: 7525045
[TBL] [Abstract][Full Text] [Related]
28. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Fisher RI
Cancer Chemother Pharmacol; 1997; 40 Suppl():S42-6. PubMed ID: 9272133
[TBL] [Abstract][Full Text] [Related]
30. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Cooper IA; Wolf MM; Robertson TI; Fox RM; Matthews JP; Stone JM; Ding JC; Dart G; Matthews J; Firkin FC
J Clin Oncol; 1994 Apr; 12(4):769-78. PubMed ID: 7512131
[TBL] [Abstract][Full Text] [Related]
31. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
32. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
33. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
Vitolo U; Bertini M; Brusamolino E; Cavallero GB; Comotti B; Gallo E; Ghio R; Levis A; Luxi G; Meneghini V
J Clin Oncol; 1992 Feb; 10(2):219-27. PubMed ID: 1370690
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.
Straus DJ; Huang J; Testa MA; Levine AM; Kaplan LD
J Clin Oncol; 1998 Nov; 16(11):3601-6. PubMed ID: 9817281
[TBL] [Abstract][Full Text] [Related]
35. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
37. Stage I non-Hodgkin's lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy.
Villikka K; Muhonen T; Ristamäki R; Teerenhovi L; Joensuu H
Acta Oncol; 1997; 36(6):619-24. PubMed ID: 9408153
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD
Blood; 1996 Nov; 88(10):3919-25. PubMed ID: 8916958
[TBL] [Abstract][Full Text] [Related]
39. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
40. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
